Feature | Cath Lab | May 07, 2018| Simon Trinh and Jeffrey Wong

Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology Market

Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Major mergers in interventional cardiology.

Major mergers in interventional cardiology.

The European interventional cardiology market is currently valued at nearly $1.4 billion. This is a mature market that has been in decline for many years as a result of market-wide factors, such as lack of innovation, consistent price erosion and increased competition. In recent years, the interventional cardiology market has been experiencing a period of consolidation, whereby large competitors are entering new market segments organically or through strategic mergers and acquisitions. This has resulted in tremendous downward pricing pressure, as consolidated companies have more power to bundle various devices at a discount in order to win tenders and contract offers with hospitals and labs.

Recent Mergers and Acquisition in Interventional Cardiology
A closer analysis of recent market transactions reveals that deals are, on average, becoming increasingly large in size. This trend is not unique to interventional cardiology markets and is prevalent in other mature medical device markets as well. Market segments that are smaller in size — like vascular closure devices, optical coherenace tomography (OCT) catheters and fractional flow reserve (FFR) guidewires — will be affected the most by recent market transactions. Recent cardiology mergers include:

Philips Acquires Spectranetics, Expanding its Image-guided Therapy Device Offerings

Abbott Completes Acquisition of St. Jude Medical

Teleflex to Acquire Vascular Solutions

Philips Acquires Volcano for $1 Billion to Expand Position in Interventional Lab Market

 

 

VCD Market Has the Greatest Downside
The vascular closure devices (VCD) market segment is expected to be amongst the most negatively affected in the market, as the anticipated price erosion will outpace growth in sales volume. In addition, there has been a continual drop in the rate of complications with VCDs, mainly due to doctors becoming selective in the way that they use closure devices. This benefits physicians and patients but reduces vascular closure device sales and the market, overall.

Read the article "Advances and Trends in Vascular Closure Devices."

 

FFR Guidewire Market Benefiting From Price Erosion
The FFR guidewire market segment is expected to be the fastest-growing in the European interventional cardiology market, as price erosions will lead to even greater increases in device adoption and, therefore, unit sales. In addition, St. Jude Medical (now Abbott) recently released the PressureWire X Guidewire, which has demonstrated improved outcomes with complex anatomies, allowing physicians the option to use FFR guidewires in a wider range of patients.  Furthermore, new companies are expected to enter this market in the coming years, which will lead to more research and development in the area.

Read the article "What is New in FFR Technology."
 

 

 

OCT Catheter Market
The OCT catheter market segment will also see an increase in market value, due to increased competition and adoption rates. Until recently, St. Jude Medical was the only competitor in the space and in 2017 the company was acquired by Abbott. Terumo is also gaining progress in this space with the Fastview OCT catheter. Increased competition in this market is healthy and will likely result in more research and development. In addition, adoption rates are expected to increase across Europe, due to growing awareness of the advantages of OCT, such as assisting in optimum stent placement locations and verifying correct stent deployment.

Read the article "Read the article "Optical Coherence Topography Offers Superior Resolution in Coronary Stent Implantation."
 

In conclusion, despite lackluster growth across the majority of the market, certain devices, such as FFR guidewires and OCT catheters, are expected to exhibit strong growth over the next several years. These markets have been affected by some major market transactions recently and will experience faster rates of price erosion, due to product bundling. However, unit sales growth will ultimately exceed price declines and lead to overall market growth for these two markets.

Editor's note: Simon Trinh is a senior research analyst at iData Research. He was the lead researcher on the latest research covering the interventional cardiology market in Europe. Jeff Wong is the analyst director at iData Research. He has been involved in numerous cardiology market research projects and now leads a team involved in that market and many others. For more information idataresearch.com.

References:

1. European Market Report Suite for Interventional Cardiology Devices Market 2018 – MedSuite, iData Research Inc.
https://idataresearch.com/product/interventional-cardiology-devices-market-europe-units-sold-average-selling-prices-procedure-volumes-market-values-shares-product-pipeline-forecasts-swot-coronary-stents-coronary-balloon/?utm_source=DAIC&utm_medium=article&utm_campaign=EUIC18_article.

 

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
Overlay Init